A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase III Study to Access the Efficacy and Safety of SP2086 Treated Type 2 Diabetes Patients
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
Price : $35 *
At a glance
- Drugs Retagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 31 Aug 2018 Biomarkers information updated
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 09 Jun 2015 Primary endpoint (Change From Baseline in HbA1c at Week24) has been met as results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.